Publications by authors named "Pascal Deschatelets"

Claim this Profile
T
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.
Fadi Fakhouri, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Pascal Deschatelets

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies.
Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, Pascal Deschatelets

Immunotherapy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors.
Peter Hillmen, Regina Horneff, Michael Yeh, Martin Kolev, Pascal Deschatelets

Int J Mol Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, Pascal Deschatelets

Lancet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Raymond Siu Ming Wong, Juan Ramon Navarro-Cabrera, Narcisa Sonia Comia, Yeow Tee Goh, Henry Idrobo, Pascal Deschatelets

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
With complements: C3 inhibition in the clinic.
Martin Kolev, Tara Barbour, Scott Baver, Cedric Francois, Pascal Deschatelets

Immunol Rev· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood.
Corinne J Smith, Nikki Ross, Ali Kamal, Kevin Y Kim, Elizabeth Kropf, Pascal Deschatelets

Front Immunol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Raymond S M Wong, Humphrey W H Pullon, Ismail Amine, Andrija Bogdanovic, Pascal Deschatelets

Ann Hematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
Régis Peffault de Latour, Jeff Szer, Ilene C Weitz, Alexander Röth, Britta Höchsmann, Pascal Deschatelets

Lancet Haematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inside-Out of Complement in Cancer.
Martin Kolev, Madhumita Das, Monica Gerber, Scott Baver, Pascal Deschatelets

Front Immunol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Peter Hillmen, Jeff Szer, Ilene Weitz, Alexander Röth, Britta Höchsmann, Pascal Deschatelets

N Engl J Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
Carlos de Castro, Federico Grossi, Ilene Ceil Weitz, Jaroslaw Maciejewski, Vivek Sharma, Pascal Deschatelets

Am J Hematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
David S Liao, Federico V Grossi, Delphine El Mehdi, Monica R Gerber, David M Brown, Pascal Deschatelets

Ophthalmology· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association for research in vision and ophthalmology 2007: the aging eye.
Pascal Deschatelets

IDrugs· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis